JPY 897.0
(-1.43%)
Year | Net Income | Net Income Growth |
---|---|---|
2024 | 3.2 Billion JPY | 4.02% |
2023 | 3.08 Billion JPY | 923.8% |
2022 | -374 Million JPY | -109.74% |
2021 | 3.84 Billion JPY | 456.67% |
2020 | 690 Million JPY | 38.04% |
2019 | 499.84 Million JPY | 59.36% |
2018 | 313.66 Million JPY | 209.61% |
2017 | 101.31 Million JPY | 291.22% |
2016 | 25.89 Million JPY | 113.78% |
2015 | -187.88 Million JPY | -2227.58% |
2014 | 8.83 Million JPY | -96.72% |
2013 | 269.34 Million JPY | 348.66% |
2012 | 60.03 Million JPY | 228.82% |
2011 | -46.6 Million JPY | -405.67% |
2010 | 15.24 Million JPY | 107.34% |
2009 | -207.57 Million JPY | 54.38% |
2008 | -455.01 Million JPY | 0.0% |
Year | Net Income | Net Income Growth |
---|---|---|
2024 Q1 | 286 Million JPY | -85.79% |
2024 Q4 | 1.34 Billion JPY | 23.99% |
2024 Q2 | 482 Million JPY | 68.53% |
2024 Q3 | 1.08 Billion JPY | 125.73% |
2023 FY | 3.08 Billion JPY | 923.8% |
2023 Q2 | 906 Million JPY | 149.75% |
2023 Q4 | 2.01 Billion JPY | 1.56% |
2023 Q1 | -1.82 Billion JPY | -1923.33% |
2023 Q3 | 1.98 Billion JPY | 118.76% |
2022 Q4 | -90 Million JPY | 95.12% |
2022 FY | -374 Million JPY | -109.74% |
2022 Q3 | -1.84 Billion JPY | -659.09% |
2022 Q2 | 330 Million JPY | -73.19% |
2022 Q1 | 1.23 Billion JPY | -46.18% |
2021 Q2 | 980.2 Million JPY | 168.68% |
2021 FY | 3.84 Billion JPY | 456.67% |
2021 Q4 | 2.28 Billion JPY | 14.3% |
2021 Q3 | 2 Billion JPY | 104.13% |
2021 Q1 | -1.42 Billion JPY | -261.24% |
2020 FY | 690 Million JPY | 38.04% |
2020 Q4 | 885.09 Million JPY | -34.04% |
2020 Q3 | 1.34 Billion JPY | 278.12% |
2020 Q1 | -782.67 Million JPY | -236.72% |
2020 Q2 | -753.39 Million JPY | 3.74% |
2019 Q2 | 135.81 Million JPY | 135.55% |
2019 FY | 499.84 Million JPY | 59.36% |
2019 Q4 | 572.46 Million JPY | 229.79% |
2019 Q1 | -382.02 Million JPY | -175.16% |
2019 Q3 | 173.58 Million JPY | 27.81% |
2018 Q4 | 508.24 Million JPY | -21.85% |
2018 Q2 | -385.69 Million JPY | 16.01% |
2018 Q1 | -459.23 Million JPY | -262.33% |
2018 FY | 313.66 Million JPY | 209.61% |
2018 Q3 | 650.34 Million JPY | 268.62% |
2017 Q3 | 302.54 Million JPY | 611.67% |
2017 FY | 101.31 Million JPY | 291.22% |
2017 Q4 | 282.89 Million JPY | -6.5% |
2017 Q2 | -59.12 Million JPY | 86.09% |
2017 Q1 | -424.99 Million JPY | -240.81% |
2016 FY | 25.89 Million JPY | 113.78% |
2016 Q2 | -70.96 Million JPY | 79.03% |
2016 Q1 | -338.48 Million JPY | -800.34% |
2016 Q3 | 133.51 Million JPY | 288.14% |
2016 Q4 | 301.82 Million JPY | 126.06% |
2015 Q3 | 28.91 Million JPY | 128.43% |
2015 Q2 | -101.67 Million JPY | 37.8% |
2015 Q1 | -163.45 Million JPY | -231.27% |
2015 FY | -187.88 Million JPY | -2227.58% |
2015 Q4 | 48.33 Million JPY | 67.18% |
2014 Q4 | 124.51 Million JPY | 196.79% |
2014 Q1 | 15.88 Million JPY | -85.86% |
2014 FY | 8.83 Million JPY | -96.72% |
2014 Q2 | -2.92 Million JPY | -118.41% |
2014 Q3 | -128.64 Million JPY | -4301.13% |
2013 FY | 269.34 Million JPY | 348.66% |
2013 Q1 | 79.36 Million JPY | -46.5% |
2013 Q2 | 43.15 Million JPY | -45.63% |
2013 Q3 | 34.52 Million JPY | -20.0% |
2013 Q4 | 112.3 Million JPY | 225.34% |
2012 Q4 | 148.35 Million JPY | 931.83% |
2012 FY | 60.03 Million JPY | 228.82% |
2012 Q2 | -77.75 Million JPY | -211.64% |
2012 Q3 | 14.37 Million JPY | 118.49% |
2012 Q1 | -24.94 Million JPY | -179.33% |
2011 Q2 | 1.29 Million JPY | 102.35% |
2011 FY | -46.6 Million JPY | -405.67% |
2011 Q4 | 31.44 Million JPY | 228.79% |
2011 Q3 | -24.41 Million JPY | -1990.02% |
2011 Q1 | -54.92 Million JPY | -474.52% |
2010 Q2 | 34.35 Million JPY | 167.73% |
2010 FY | 15.24 Million JPY | 107.34% |
2010 Q1 | -50.72 Million JPY | -610.08% |
2010 Q4 | 14.66 Million JPY | -13.49% |
2010 Q3 | 16.95 Million JPY | -50.66% |
2009 Q4 | 9.94 Million JPY | 109.79% |
2009 Q3 | -101.53 Million JPY | -137.97% |
2009 Q1 | -73.31 Million JPY | 0.0% |
2009 FY | -207.57 Million JPY | 54.38% |
2009 Q2 | -42.66 Million JPY | 41.81% |
2008 FY | -455.01 Million JPY | 0.0% |
Name | Net Income | Net Income Difference |
---|---|---|
Takeda Pharmaceutical Company Limited | 144.06 Billion JPY | 97.775% |
Sumitomo Pharma Co., Ltd. | -314.96 Billion JPY | 101.018% |
Shionogi & Co., Ltd. | 162.03 Billion JPY | 98.022% |
Wakamoto Pharmaceutical Co.,Ltd. | 108.95 Million JPY | -2841.473% |
Nippon Shinyaku Co., Ltd. | 25.85 Billion JPY | 87.602% |
Kaken Pharmaceutical Co., Ltd. | 8.02 Billion JPY | 60.062% |
Eisai Co., Ltd. | 42.4 Billion JPY | 92.442% |
Morishita Jintan Co., Ltd. | 697 Million JPY | -359.828% |
Hisamitsu Pharmaceutical Co., Inc. | 13.96 Billion JPY | 77.056% |
Mochida Pharmaceutical Co., Ltd. | 4.54 Billion JPY | 29.514% |
Fuso Pharmaceutical Industries,Ltd. | 1.37 Billion JPY | -132.752% |
Nippon Chemiphar Co., Ltd. | -180 Million JPY | 1880.556% |
Tsumura & Co. | 16.7 Billion JPY | 80.816% |
Kissei Pharmaceutical Co., Ltd. | 11.16 Billion JPY | 71.281% |
Torii Pharmaceutical Co., Ltd. | 4.11 Billion JPY | 22.19% |
Towa Pharmaceutical Co., Ltd. | 16.17 Billion JPY | 80.183% |
Fuji Pharma Co., Ltd. | 3.43 Billion JPY | 6.696% |
Zeria Pharmaceutical Co., Ltd. | 7.73 Billion JPY | 58.545% |
KYORIN Holdings, Inc. | 5.32 Billion JPY | 39.778% |
Taiko Pharmaceutical Co.,Ltd. | -4.89 Billion JPY | 165.488% |
Daito Pharmaceutical Co.,Ltd. | 3.29 Billion JPY | 2.731% |
SymBio Pharmaceuticals Limited | -1.96 Billion JPY | 263.286% |
MedRx Co., Ltd | -932 Million JPY | 443.884% |
Mizuho Medy Co.,Ltd. | 3.77 Billion JPY | 15.082% |
Solasia Pharma K.K. | -1.11 Billion JPY | 388.219% |
Modalis Therapeutics Corporation | -2.39 Billion JPY | 233.998% |
ASKA Pharmaceutical Holdings Co.,Ltd. | 7.54 Billion JPY | 57.522% |
Sawai Group Holdings Co., Ltd. | 13.69 Billion JPY | 76.597% |
Cyfuse Biomedical K.K. | -589.21 Million JPY | 643.948% |
Toho Holdings Co., Ltd. | 20.65 Billion JPY | 84.485% |
Koa Shoji Holdings Co.,Ltd. | 2.94 Billion JPY | -8.779% |